Skip to main content

Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.

Publication ,  Conference
Slingluff, CL; Fling, S; Mauldin, IS; Ernstoff, MS; Hanks, BA; Delman, KA; Lawson, DH; Gastman, B; Kaiser, JC; Cheever, MA
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

3033 / 3033

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Slingluff, C. L., Fling, S., Mauldin, I. S., Ernstoff, M. S., Hanks, B. A., Delman, K. A., … Cheever, M. A. (2018). Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. In Journal of Clinical Oncology (Vol. 36, pp. 3033–3033). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.3033
Slingluff, Craig L., Steven Fling, Ileana S. Mauldin, Marc S. Ernstoff, Brent Allen Hanks, Keith A. Delman, David H. Lawson, Brian Gastman, Judith C. Kaiser, and Martin A. Cheever. “Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.” In Journal of Clinical Oncology, 36:3033–3033. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3033.
Slingluff CL, Fling S, Mauldin IS, Ernstoff MS, Hanks BA, Delman KA, et al. Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3033–3033.
Slingluff, Craig L., et al. “Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3033–3033. Crossref, doi:10.1200/jco.2018.36.15_suppl.3033.
Slingluff CL, Fling S, Mauldin IS, Ernstoff MS, Hanks BA, Delman KA, Lawson DH, Gastman B, Kaiser JC, Cheever MA. Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3033–3033.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

3033 / 3033

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences